These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 26735216

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F, Seto T, Yamanaka T, Toyozawa R, Inamasu E, Kojo M, Toyokawa G, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y.
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G.
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [Abstract] [Full Text] [Related]

  • 7. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
    Ho IW, Pan YL, Lai JI, Liu CY.
    Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
    [Abstract] [Full Text] [Related]

  • 8. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
    Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, Livingston R, Johnson DH.
    Cancer; 2001 Jun 01; 91(11):2010-5. PubMed ID: 11391579
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma.
    Zhai Y, Hui Z, Ji W, Wang X, Liang J, Mao Y, Luo Y, Zou S, Lv J, Zhou Z, Chen D, Zhang H, Xiao Z, Wang L, Feng Q.
    Ann Thorac Surg; 2017 Nov 01; 104(5):1718-1724. PubMed ID: 28969896
    [Abstract] [Full Text] [Related]

  • 11. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A.
    J Clin Oncol; 2018 Feb 01; 36(4):342-349. PubMed ID: 29240542
    [Abstract] [Full Text] [Related]

  • 12. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
    Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M.
    Lung Cancer; 2011 Dec 01; 74(3):492-6. PubMed ID: 21665316
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma.
    Shao K, Hao Y, Xu M, Shi Z, Lin G, Xu C, Zhang Y, Song Z.
    Clin Oncol (R Coll Radiol); 2024 Nov 01; 36(11):710-718. PubMed ID: 38777703
    [Abstract] [Full Text] [Related]

  • 14. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience.
    Grassin F, Paleiron N, André M, Caliandro R, Bretel JJ, Terrier P, Margery J, Le Chevalier T, Ruffié P.
    J Thorac Oncol; 2010 Jun 01; 5(6):893-7. PubMed ID: 20521356
    [Abstract] [Full Text] [Related]

  • 15. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
    Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N.
    Lancet Oncol; 2020 Jun 01; 21(6):843-850. PubMed ID: 32502444
    [Abstract] [Full Text] [Related]

  • 16. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
    Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y.
    Anticancer Res; 2014 Oct 01; 34(10):5743-7. PubMed ID: 25275083
    [Abstract] [Full Text] [Related]

  • 17. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
    Oshita F, Kasai T, Kurata T, Fukuda M, Yamamoto N, Ohe Y, Tamura T, Eguchi K, Shinkai T, Saijo N.
    Jpn J Clin Oncol; 1995 Oct 01; 25(5):208-12. PubMed ID: 7474409
    [Abstract] [Full Text] [Related]

  • 18. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
    Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K, North East Japan Study Group.
    Oncologist; 2020 Apr 01; 25(4):e668-e674. PubMed ID: 31771990
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
    Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K, North East Japan Study Group.
    Oncologist; 2018 Oct 01; 23(10):1210-1217. PubMed ID: 29567820
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, Tanaka H, Watanabe K, Mori Y, Harada T, Hino T, Fujii M, Ichinose M.
    Lung Cancer; 2020 Jan 01; 139():89-93. PubMed ID: 31751805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.